Jeff Yass’s CytomX Therapeutics CTMX Stock Holding History

Jeff Yass’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$307K	Sell	81,900 -825,900	-91%	-$3.15M	﹤0.01%	10990
2026 Q1	$4.27M	Buy	907,800 +887,200	+4,307%	+$4.5M	﹤0.01%	4531
2025 Q4	$87.8K	Sell	20,600 -181,200	-90%	-$688K	﹤0.01%	11525
2025 Q3	$644K	Buy	201,800 +186,900	+1,254%	+$421K	﹤0.01%	8398
2025 Q2	$33.8K	Buy	+14,900	New	+$24K	﹤0.01%	12223
2024 Q3	–	Sell	-15,300	Closed	-$18.7K	–	12133
2024 Q2	$18.7K	Buy	+15,300	New	+$30.5K	﹤0.01%	11678
2023 Q2	–	Sell	-28,000	Closed	-$42.3K	–	12204
2023 Q1	$42.3K	Buy	+28,000	New	+$63.3K	﹤0.01%	11758
2022 Q1	–	Sell	-21,700	Closed	-$94K	–	13112
2021 Q4	$94K	Sell	21,700 -9,900	-31%	-$58K	﹤0.01%	12183
2021 Q3	$161K	Buy	31,600 +4,200	+15%	+$22.5K	﹤0.01%	11733
2021 Q2	$173K	Buy	27,400 +6,400	+30%	+$49.8K	﹤0.01%	11737
2021 Q1	$162K	Buy	+21,000	New	+$166K	﹤0.01%	11589
2018 Q4	–	Sell	-24,800	Closed	-$459K	–	9060
2018 Q3	$459K	Buy	24,800 +13,400	+118%	+$305K	﹤0.01%	6693
2018 Q2	$261K	Buy	+11,400	New	+$291K	﹤0.01%	8115

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Jeff Yass's CTMX Position: Q2 2026 in Review

Jeff Yass reduced its CytomX Therapeutics (CTMX) stake by 95% in Q2 2026, selling an estimated $6.79M and leaving 90,673 shares worth $340K. The position accounts for ﹤0.01% of the portfolio, ranked #10771.

Jeff Yass first reported a position in CTMX in Q4 2015 and has held it in 31 quarters since. The position peaked at $8.79M in Q1 2026. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Jeff Yass held 90,673 shares of CytomX Therapeutics worth $340K as of Q2 2026.
Jeff Yass sold 1,778,942 CytomX Therapeutics shares in Q2 2026, an estimated $6.79M.
CytomX Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10771 holding.
Jeff Yass first reported a position in CytomX Therapeutics in Q4 2015 and has held it in 31 quarters since.
Jeff Yass's CytomX Therapeutics position peaked at $8.79M in Q1 2026.
178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.